drugset / Trial / NCT06145217

An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

NCT06145217

Phase 1 Completed 18 enrolled Xspray Pharma AB
NaSingle-groupOpen-labelTreatment

Summary

A drug-drug interaction study designed to evaluate the drug-drug interaction between SPRYCEL® 100 mg (US sourced) and Omeprazole in healthy, adult, human subjects

Timeline

Start
2023-08-22
Primary completion
2023-08-22
Completion
2023-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Omeprazole Other / unclassified 40 mg
Subject dasatinib anhydrous Small molecule 100 mg

Indications

No indication recorded.